Loading...
Market
Will insulin prices decrease by more than 10% due to FTC action by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Publicly available insulin price indexes or reports from reputable sources like the American Diabetes Association
Story
FTC Sues CVS, Cigna, UnitedHealth PBMs Over Inflated Insulin Prices, Rebate Programs
Sep 20, 2024, 05:03 PM
The Federal Trade Commission (FTC) has filed a lawsuit against the three largest pharmacy benefit managers (PBMs) in the United States: CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx. The FTC accuses these PBMs of engaging in illegal rebate programs that have artificially inflated the cost of insulin by over 1,200 percent over the past two decades. The lawsuit, filed on Friday, alleges that these companies steered diabetic patients towards higher-priced insulin products to reap millions of dollars in rebates from pharmaceutical companies, thereby increasing their profits at the expense of patients. These three PBMs administer 80% of prescriptions in the US. The FTC's action aims to address these anticompetitive practices and restore competition in the insulin market.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Insulin prices decrease significantly • 25%
Insulin prices decrease slightly • 25%
Insulin prices remain the same • 25%
Insulin prices increase • 25%
Additional PBMs sued • 25%
Pharmaceutical companies sued • 25%
Both PBMs and pharmaceutical companies sued • 25%
No additional legal actions • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Eli Lilly • 33%
Novo Nordisk • 33%
Sanofi • 33%
None • 33%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%